Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 14.35% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 1.14% year-over-year, with the annual reading at $7.3 million for FY2025, 1.14% up from the prior year.
  • Depreciation & Amortization (CF) hit $1.6 million in Q4 2025 for Sutro Biopharma, down from $1.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2025 to a low of $1.1 million in Q3 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): rose 28.62% in 2022 and later fell 14.35% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $1.3 million in 2021, then grew by 16.2% to $1.5 million in 2022, then rose by 12.24% to $1.7 million in 2023, then rose by 8.92% to $1.9 million in 2024, then decreased by 14.35% to $1.6 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for STRO at $1.6 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.